There has been a significant increase in interest in using the nasal route to administer peptides. This is mainly due to its advantages, including less invasiveness, rapid absorption, and the ability to bypass initial metabolism in the liver. The incorporation of nanotechnology has emerged as a prominent strategy, with nanocarriers such as nanoparticles and liposomes being employed to augment stability and bioavailability of peptides, as extensively discussed in this review. These carriers serve the crucial function of safeguarding peptides against enzymatic degradation while also enabling a sustained release, thus extending the therapeutic impact. Additionally, this review delves into mucoadhesive polymers and permeation enhancers, which have undergone extensive exploration to enhance nasal retention and augment the transportation of peptides across the nasal mucosa. Recent breakthroughs in nasal peptide delivery have heralded a new era in peptide-based therapies. These advancements encompass innovative formulation technologies, the utilization of nanocarriers, permeation enhancers, and the integration of intelligent materials and nasal drug delivery devices, all of which are geared towards enhancing the efficiency and efficacy of nasal peptide delivery.
Background: Diabetes mellitus (DM) is an autoimmune manifestation defined by persistent hyperglycemia and alterations in protein, fatty substances, and carbohydrate metabolism as an effect of problems with the secretion of insulin action or both. Manifestations include thirst, blurred eyesight, weight loss, and ketoacidosis, which can majorly lead to coma. There are different types of diabetes according to class or by cellular level. They are interrelated with hyperlipidemia as they are involved in the metabolism and regulation of physiological factors. Most parameters are seen at cellular or humoral levels, yet the underlying concern remains the same. Objective: To create a systematic correlation between the disease and locate the exact mechanism and receptors responsible for it. So, this article covers a proper way to resolve the conditions and their manifestation through literacy and diagrammatic. Conclusion: Hence, this will be an insight for many scholars to understand the exact mechanism involved in the process.
Sodium-glucose cotransporter-2 inhibitors, often known as SGLT2Is, are a class of medications used largely for anti-diabetic activity in oral dose form that lowers blood glucose levels. In recent years, numerous trials have documented the use of medications for conditions including renal and cardiovascular illness that go beyond only decreasing blood sugar. Other benefits of SGLT2Is' glucose-lowering activities include slowing or halting the progression of chronic kidney disease, lowering estimated glomerular filtration rate, lowering albuminuria, improving renal and cardiovascular health, and reducing estimated glomerular filtration rate. Published clinical trials reported all of these SGLT2I effects. The studies that we reviewed for this article are the Canagliflozin CardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA - CKD) trial, Effects of SGLT2I dapagliflozin on Proteinuria in Non-Diabetic Patients with The clinical studies, SGPLT2I class of medications, and their impact on cardiovascular and renal illnesses in diabetic and non-diabetic individuals are adequately covered in this review study. Keywords: SGLT2Is, Chronic kidney disease, dapagliflozin, Canagliflozin